Clinical Trials

Eli Lilly’s $2.75 Billion Insilico Deal Marks Enterprise AI’s Shift From Hype to Production

Big Pharma's largest generative AI partnership validates vertical specialization over generalist models—and signals that geopolitics won't block deals where ROI is measurable.